S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

Arca Biopharma Stock Price, Forecast & Analysis (NASDAQ:ABIO)

$5.28
+0.17 (+3.33 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$5.11
Now: $5.28
$5.35
50-Day Range
$5.05
MA: $5.24
$5.47
52-Week Range
$4.68
Now: $5.28
$20.45
Volume12,900 shs
Average Volume278,416 shs
Market Capitalization$8.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
ARCA biopharma, Inc. is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic HF. It has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABIO
CUSIPN/A
Phone720-940-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.52 per share

Profitability

Net Income$-7,930,000.00

Miscellaneous

Employees15
Market Cap$8.42 million
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable

Receive ABIO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.


Arca Biopharma (NASDAQ:ABIO) Frequently Asked Questions

What is Arca Biopharma's stock symbol?

Arca Biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How were Arca Biopharma's earnings last quarter?

Arca Biopharma Inc (NASDAQ:ABIO) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.30) by $0.54. View Arca Biopharma's Earnings History.

When is Arca Biopharma's next earnings date?

Arca Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Arca Biopharma.

What price target have analysts set for ABIO?

1 brokers have issued 12-month target prices for Arca Biopharma's shares. Their forecasts range from $17.00 to $17.00. On average, they anticipate Arca Biopharma's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 222.0% from the stock's current price. View Analyst Price Targets for Arca Biopharma.

What is the consensus analysts' recommendation for Arca Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arca Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arca Biopharma.

Has Arca Biopharma been receiving favorable news coverage?

News articles about ABIO stock have been trending very negative on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arca Biopharma earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Arca Biopharma.

Who are some of Arca Biopharma's key competitors?

What other stocks do shareholders of Arca Biopharma own?

Who are Arca Biopharma's key executives?

Arca Biopharma's management team includes the folowing people:
  • Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 74)
  • Mr. Thomas A. Keuer, Chief Operating Officer (Age 60)
  • Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 60)
  • Mr. Brian L. Selby, Chief Accounting Officer & VP of Fin. (Age 57)

How do I buy shares of Arca Biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arca Biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $5.28.

How big of a company is Arca Biopharma?

Arca Biopharma has a market capitalization of $8.42 million. Arca Biopharma employs 15 workers across the globe.View Additional Information About Arca Biopharma.

What is Arca Biopharma's official website?

The official website for Arca Biopharma is http://arcabio.com/.

How can I contact Arca Biopharma?

Arca Biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2100 or via email at [email protected]


MarketBeat Community Rating for Arca Biopharma (NASDAQ ABIO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Arca Biopharma and other stocks. Vote "Outperform" if you believe ABIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Diluted Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel